OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Release Date
2023
(2)
2022
(2)
2024
(1)
2020
(1)
2019
(1)
2018
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
Not available
S-EPMC9129205
|
biostudies-literature
Cite
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
Not available
S-EPMC11367514
|
biostudies-literature
Cite
Efficient recall of SARS-CoV-2 variant-reactive B cells and T responses in the elderly upon heterologous mRNA vaccines as boosters.
Not available
S-EPMC9874655
|
biostudies-literature
Cite
Use of Telemedicine for Postdischarge Assessment of the Surgical Wound: International Cohort Study, and Systematic Review With Meta-analysis.
Not available
S-EPMC10174106
|
biostudies-literature
Cite
Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study.
Not available
S-EPMC5910057
|
biostudies-literature
Cite
Surgical site infection after gastrointestinal surgery in children: an international, multicentre, prospective cohort study.
Not available
S-EPMC7716674
|
biostudies-literature
Cite
Global economic burden of unmet surgical need for appendicitis.
Not available
S-EPMC10364778
|
biostudies-literature
Cite
Global variation in anastomosis and end colostomy formation following left-sided colorectal resection.
Not available
S-EPMC6921967
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets